# AALL2131 (NCT06124157)

> A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)

No report yet. It can be ordered.

- Drugs tested: blinatumomab plus dasatinib; blinatumomab plus imatinib
- Indication: newly-diagnosed Ph+ or ABL-class Ph-like B-ALL

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT06124157
- Phase: PHASE2
- Status: RECRUITING
- Sponsor: National Cancer Institute (NCI)
- Conditions: B Acute Lymphoblastic Leukemia
- Interventions: Biospecimen Collection; Blinatumomab; Bone Marrow Biopsy; Calaspargase Pegol; Cyclophosphamide; Cytarabine; Dasatinib; Daunorubicin; Doxorubicin; Echocardiography Test; Imatinib; Leucovorin; Mercaptopurine; Methotrexate; Multigated Acquisition Scan; Pegaspargase; Prednisolone; Prednisone; Radiation Therapy; Thioguanine; Vincristine
- Enrollment: 222
- Primary outcome: Philadelphia chromosome-positive (Ph+) (BCR::ABL1-rearranged) 3-year event free survival (EFS)
- Primary outcome: ABL-class Ph-like B-ALL 3-year event free survival (EFS)
- Primary outcome: Incidence of adverse events

## Indexed commentary on AALL2131 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- X threads: 2
- YouTube: 1

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=aall2131-nct06124157